within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03A_DrugsForFunctionalGastrointestinalDisorders.A03AX01_Fenpiprane;

model Fenpiprane
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.15,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fenpiprane</td></tr><tr><td>ATC code:</td><td>A03AX01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>150</td><td>L</td></tr>
    <tr><td>clearance:</td><td>15</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fenpiprane is an antimuscarinic agent formerly used as an antispasmodic for the treatment of functional gastrointestinal disorders such as irritable bowel syndrome. It is not approved or widely used today in clinical practice.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies reporting quantitative PK parameters for fenpiprane in humans were found. The following values are theoretical estimates based on typical values for orally administered antispasmodic compounds in adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03AX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fenpiprane;
